Last Updated: May 3, 2026

Claims for Patent: 12,268,662

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,268,662

Title:	Formulations comprising carbachol and brimonidine to enhance anti- presbyopia effects
Abstract:	The present disclosure is directed to ophthalmic formulations comprising carbachol, processes for preparing ophthalmic formulations comprising carbachol, and methods of treating presbyopia and other ophthalmic conditions by administering ophthalmic formulations comprising carbachol to a subject in need thereof.
Inventor(s):	Rhett Schiffman, Bruce FIRESTONE
Assignee:	Pharmassist Cmc Consulting LLC , Visus Therapeutics Inc
Application Number:	US18/531,082
Patent Claims:	1. An ophthalmic formulation comprising 2.75 wt % carbachol, or a pharmaceutically acceptable salt thereof, 0.1 wt % brimonidine, or a pharmaceutically acceptable salt thereof, 0.2 wt % hydroxypropylmethyl cellulose (HPMC), and a phosphate buffer, wherein the ophthalmic formulation does not contain a preservative. 2. The ophthalmic formulation of claim 1, wherein the phosphate buffer comprises sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate. 3. The ophthalmic formulation of claim 1, wherein the pH of the formulation is from about 7.2 to about 7.6. 4. The ophthalmic formulation of claim 3, wherein the pH of the formulation is about 7.4. 5. The ophthalmic formulation of claim 1, wherein the brimonidine is brimonidine tartrate. 6. A method for ameliorating or reducing presbyopia in a subject in need thereof comprising administering to at least one eye of the subject the ophthalmic formulation of claim 1. 7. The method of claim 6, wherein the phosphate buffer comprises sodium phosphate monobasic monohydrate and sodium phosphate dibasic heptahydrate. 8. The method of claim 6, wherein the pH of the ophthalmic formulation is from about 7.2 to about 7.6. 9. The method of claim 6, wherein the pH of the ophthalmic formulation is about 7.4. 10. The method of claim 6, wherein the brimonidine is brimonidine tartrate. 11. The method of claim 6, wherein the amelioration or reduction of presbyopia is effective for at least 9 hours.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.